Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel, Phase I Pharmacokinetic Trial Comparing The Potential Biosimilar ALT02(Trastuzumab) With Herceptin in Healthy Volunteers

NCT03242239 is registered in ClinicalTrials.gov with Alteogen, Inc. as lead sponsor.

NCT NCT03242239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03242239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel, Phase I Pharmacokinetic Trial Comparing The Potential Biosimilar ALT02(Trastuzumab) With Herceptin in Healthy Volunteers
Lead sponsor
Alteogen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 9, 2016
Completion date
September 30, 2016
Enrollment
105 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy